全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

基于非监督学习和多层网络分析袁肇凯教授治疗甲状腺结节的证治思路
Evidence-Based Treatment Approaches of Professor Yuan Zhaokai for Thyroid Nodules Based on Unsupervised Learning and Multilayer Network Analysis

DOI: 10.12677/tcm.2025.143174, PP. 1156-1171

Keywords: 甲状腺结节,数据挖掘,网络药理学,用药规律,中医药
Thyroid Nodules
, Data Mining, Network Pharmacology, Medication Patterns, Traditional Chinese Medicine

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的:本研究通过非监督学习和多层网络分析袁肇凯教授治疗良性甲状腺结节的用药规律和治疗思路,为甲状腺结节的中医药临床治疗提供新思路。方法:收集2023年6月30日至2024年6月30日袁教授治疗甲状腺结节的192张中医处方,采用描述统计、关联规则、聚类分析等方法筛选高频药物和组方,并结合网络药理学分析药物活性成分及作用机制。通过构建药物–靶点–疾病的网络,探索药物与疾病之间的相互关系。结果:研究发现袁教授常用药物主要包括活血化瘀药、化痰止咳药、清热药,治疗策略以化痰散结、清热解毒、疏肝解郁为主。数据挖掘揭示了两组核心组方,分别侧重祛痰清热和活血化瘀,符合甲状腺结节的“痰瘀互结”病机。网络药理学分析表明,这些中药成分通过调节多个靶点(如TNF-α、IL-6)和信号通路(如NF-κB、MAPK通路),增强了治疗效果。结论:研究为袁教授的治疗策略提供了科学依据,表明中药复方通过多靶点、多通路的机制发挥作用。未来需要进一步的临床验证及分子机制研究,为中医药治疗甲状腺结节提供更多证据。
Objective: This study aims to explore the medication patterns and treatment strategies of Professor Yuan Zhaokai in the treatment of benign thyroid nodules using unsupervised learning and multilayer network analysis, thereby providing new perspectives for clinical treatment of thyroid nodules with Traditional Chinese Medicine (TCM). Methods: A total of 192 TCM prescriptions used by Professor Yuan in treating thyroid nodules from June 30, 2023, to June 30, 2024, were collected. High-frequency medications and formulas were identified through descriptive statistics, association rules, and cluster analysis. Additionally, network pharmacology was employed to analyze the active components and mechanisms of action of the medications. By constructing drug-target-disease networks, the interactions between drugs and diseases were explored. Results: The study identified that Professor Yuan frequently used blood-activating and stasis-dispelling drugs, phlegm-resolving and cough-suppressing bronchodilator herbs, and heat-clearing herbs. The primary treatment strategies focused on resolving phlegm and dispersing nodules, clearing heat and detoxifying, and soothing the liver and alleviating depression. Data mining revealed two core formula groups, emphasizing phlegm clearance and heat elimination, and blood activation and stasis dissolution, aligning with the pathogenic mechanism of “phlegm and blood stasis intermingling” in thyroid nodules. Network pharmacology analysis indicated that these TCM components enhance therapeutic effects by regulating multiple targets (e.g., TNF-α, IL-6) and signaling pathways (e.g., NF-κB, MAPK pathways). Conclusion: This study provides scientific support for Professor Yuan’s treatment strategies, demonstrating that TCM formulas act through multi-target and multi-pathway mechanisms. Further clinical validation and molecular mechanism research are needed to provide more evidence for the TCM treatment of

References

[1]  甲状腺结节和分化型甲状腺癌诊治指南[J]. 中国肿瘤临床, 2012, 39(17): 1249-1272.
[2]  郭丽珍, 吕雄, 黄艳丽, 等. 甲状腺结节的诊察手段及中西医治疗方法概述[J]. 山东中医药大学基础医学院, 2018, 40(9): 59-64.
[3]  赵勇, 徐文华, 陈继东, 等. 中药复方治疗甲状腺结节的Meta分析[J]. 中华中医药学刊, 2015, 33(1): 192-195.
[4]  中华医学会内分泌学会《中国甲状腺疾病诊治指南》编写组. 中国甲状腺疾病诊治指南——甲状腺结节[J]. 中华内科杂志, 2008, 47(10): 867-868.
[5]  十四五规划教材 中医内科学[M]. 第5版. 郑州: 中原农民出版社, 2022.
[6]  国家药典委员会编. 中华人民共和国药典 一部 2020年版[M]. 北京: 中国医药科技出版社, 2020.
[7]  周祯祥, 吴庆光, 编. 全国中医药行业高等教育十四五规划教材 中药学 新世纪[M]. 第3版. 北京: 中国中医药出版社, 2023.
[8]  国家市场监督管理总局. 中医临床诊疗术语(第2部分): 证候: GB/T 16751.2-2021 [S]. 2021-11-26.
[9]  (明)陈实功, 原著. 刘忠恕, 张若兰, 点校. 外科正宗[M]. 天津: 天津科学技术出版社, 1993.
[10]  冯伟, 李平, 暴雪丽, 等. 226例甲状腺结节患者的证候要素及应证组合研究[J]. 辽宁中医杂志, 2023, 50(7): 16-19.
[11]  仝小林. 态靶医学——中医未来发展之路[J]. 中国中西医结合杂志, 2021, 41(1): 16-18.
[12]  (明)李时珍, 著. 朱斐译, 注. 本草纲目[M]. 南昌: 二十一世纪出版社, 全国百佳出版社, 2017.
[13]  (唐)王冰, 编次. (宋)高保衡, 林忆, 校正. 素问[M]. 北京: 中版集团数字传媒有限公司, 2020.
[14]  朱晓东, 冯敏超, 刘锟荣, 等. 基于PI3K/AKT/NF-κB信号通路探讨清解化攻方减轻急性胰腺炎炎症反应的作用机制[J/OL]. 中国药理学通报, 1-11.
http://kns.cnki.net/kcms/detail/34.1086.R.20241220.1540.002.html, 2025-03-20.
[15]  陈蕊, 王玲玲, 董家辉, 等. PD-1/PD-L1轴在新型冠状病毒感染中的研究进展[J]. 中国免疫学杂志, 2023, 39(11): 2410-2414.
[16]  Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., et al. (2022) Targeting PI3K/AKT Signaling for Treatment of Idiopathic Pulmonary Fibrosis. Acta Pharmaceutica Sinica B, 12, 18-32.
https://doi.org/10.1016/j.apsb.2021.07.023

[17]  Thomas, C.M., Asa, S.L., Ezzat, S., Sawka, A.M. and Goldstein, D. (2019) Diagnosis and Pathologic Characteristics of Medullary Thyroid Carcinoma—Review of Current Guidelines. Current Oncology, 26, 338-344.
https://doi.org/10.3747/co.26.5539

[18]  Sezer, E.D., Oktay, L.M., Karadadaş, E., Memmedov, H., Selvi Gunel, N. and Sözmen, E. (2019) Assessing Anticancer Potential of Blueberry Flavonoids, Quercetin, Kaempferol, and Gentisic Acid, through Oxidative Stress and Apoptosis Parameters on HCT-116 Cells. Journal of Medicinal Food, 22, 1118-1126.
https://doi.org/10.1089/jmf.2019.0098

[19]  Jiang, M., Zhu, M., Wang, L. and Yu, S. (2019) Anti-Tumor Effects and Associated Molecular Mechanisms of Myricetin. Biomedicine & Pharmacotherapy, 120, Article ID: 109506.
https://doi.org/10.1016/j.biopha.2019.109506

[20]  Khan, Z., Nath, N., Rauf, A., Emran, T.B., Mitra, S., Islam, F., et al. (2022) Multifunctional Roles and Pharmacological Potential of β-Sitosterol: Emerging Evidence toward Clinical Applications. Chemico-Biological Interactions, 365, Article ID: 110117.
https://doi.org/10.1016/j.cbi.2022.110117

[21]  Conti, P., Caraffa, A., Gallenga, C.E., Ross, R., Kritas, S.K., Frydas, I., et al. (2021) Powerful Anti‐Inflammatory Action of Luteolin: Potential Increase with IL‐38. BioFactors, 47, 165-169.
https://doi.org/10.1002/biof.1718

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133